CO2021014274A2 - Formulaciones liposomales y métodos de uso y preparación de las mismas - Google Patents

Formulaciones liposomales y métodos de uso y preparación de las mismas

Info

Publication number
CO2021014274A2
CO2021014274A2 CONC2021/0014274A CO2021014274A CO2021014274A2 CO 2021014274 A2 CO2021014274 A2 CO 2021014274A2 CO 2021014274 A CO2021014274 A CO 2021014274A CO 2021014274 A2 CO2021014274 A2 CO 2021014274A2
Authority
CO
Colombia
Prior art keywords
methods
compositions
preparation
phosphorylated
liposomal formulations
Prior art date
Application number
CONC2021/0014274A
Other languages
English (en)
Spanish (es)
Inventor
Agnes Rafalko
Teppei Shirakura
Samuel Eric Greenberg
Original Assignee
Glycomine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomine Inc filed Critical Glycomine Inc
Publication of CO2021014274A2 publication Critical patent/CO2021014274A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2021/0014274A 2019-03-29 2021-10-26 Formulaciones liposomales y métodos de uso y preparación de las mismas CO2021014274A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962826874P 2019-03-29 2019-03-29
PCT/US2020/025246 WO2020205530A1 (en) 2019-03-29 2020-03-27 Liposomal formulations, and methods of using and preparing thereof

Publications (1)

Publication Number Publication Date
CO2021014274A2 true CO2021014274A2 (es) 2022-01-17

Family

ID=72666933

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0014274A CO2021014274A2 (es) 2019-03-29 2021-10-26 Formulaciones liposomales y métodos de uso y preparación de las mismas

Country Status (19)

Country Link
US (1) US12691131B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946365A4 (cg-RX-API-DMAC7.html)
JP (1) JP7583741B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210143906A (cg-RX-API-DMAC7.html)
CN (1) CN113873998A (cg-RX-API-DMAC7.html)
AR (1) AR119705A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020252005B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019593A2 (cg-RX-API-DMAC7.html)
CA (1) CA3134828A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002512A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021014274A2 (cg-RX-API-DMAC7.html)
EA (1) EA202192663A1 (cg-RX-API-DMAC7.html)
IL (1) IL286713B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021011876A (cg-RX-API-DMAC7.html)
PE (1) PE20212366A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552428A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110623PA (cg-RX-API-DMAC7.html)
TW (1) TWI906214B (cg-RX-API-DMAC7.html)
WO (1) WO2020205530A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021011876A (es) 2019-03-29 2022-01-04 Glycomine Inc Formulaciones liposomicas y metodos de uso y preparacion de las mismas.
US20250248939A1 (en) * 2022-04-18 2025-08-07 City Of Hope Lipid nanoparticles, nucleic acids, and methods of use
TW202543582A (zh) * 2024-02-29 2025-11-16 美商葛里柯麥公司 脂質體調配物及其使用及製備方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
WO2000051565A1 (en) 1999-03-02 2000-09-08 The Liposome Company, Inc. Encapsulation of bioactive complexes in liposomes
US7060291B1 (en) * 1999-11-24 2006-06-13 Transave, Inc. Modular targeted liposomal delivery system
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
US7011845B2 (en) 2000-05-09 2006-03-14 Mcp Hahnemann University β-glucans encapsulated in liposomes
HUP0303616A3 (en) 2001-03-26 2006-07-28 Alza Corp Mountain View Liposome composition for improved intracellular delivery of a therapeutic agent
CA2471960A1 (en) 2002-01-09 2003-07-24 Elan Pharmaceuticals, Inc. Efficient liposomal encapsulation
EP1478341A4 (en) 2002-01-09 2009-05-20 Transave Inc EFFICIENT ENCAPSULATION OF NUCLEIC ACIDS IN MEDIUM SIZE LIPOSOMES
WO2004103510A2 (en) 2003-05-14 2004-12-02 The Regents Of The University Of Colorado Methods and apparatus using electrostatic atomization to form liquid vesicles
EP1643971A2 (en) 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
JP2008518925A (ja) 2004-10-29 2008-06-05 ネオファーム、インコーポレイティッド リポソーム製剤の製造プロセス
FR2897779B1 (fr) 2006-02-24 2009-04-17 Orphan Europ Sarl Manossyl-1 phosphates, procede de preparation et utilisation en therapeutique, notamment vis-a-vis dy syndrome cdg-la
KR20100127842A (ko) 2008-03-26 2010-12-06 유니버시티 오브 옥스퍼드 소포체 표적화 리포좀
CA2761916A1 (fr) * 2009-05-14 2010-11-18 Sanofi Pasteur Procede pour adjuver le lipopolysaccharide (lps) des bacteries a gram-negatif
WO2010138550A1 (en) 2009-05-27 2010-12-02 Northeastern University Conjugated nanodelivery vehicles
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
US20110257233A1 (en) 2010-03-19 2011-10-20 Sanford-Burnham Medical Research Institute Benzoisothiazolones as inhibitors of phosphomannose isomerase
EP2598120B1 (en) 2010-07-31 2018-09-05 The Scripps Research Institute Compositions and methods for inducing immune tolerance
PT2750707T (pt) 2011-08-31 2019-01-23 Glaxosmithkline Biologicals Sa Lipossomas peguilados para distribuição de arn que codifica imunogénio
HK1206644A1 (en) 2012-03-29 2016-01-15 Shire Human Genetic Therapies, Inc. Lipid-derived neutral nanoparticles
WO2014063757A1 (en) 2012-10-26 2014-05-01 Universiteit Leiden Delivery methods
CN104884637A (zh) 2012-11-05 2015-09-02 普隆奈治疗公司 利用生物标志物通过bcl2表达的调节治疗癌症的方法
ES3026657T3 (en) 2013-09-16 2025-06-11 Glycomine Inc Pharmaceutical preparation of carbohydrates for therapeutic use
US20150132369A1 (en) 2013-11-09 2015-05-14 Exir Nano Sina Company Nanoliposomal cyclosorin formulations for immunosuppresion and methods for the production thereof
CN107207614B (zh) 2014-10-09 2022-01-11 利普泰克有限公司 嵌合蛋白
US20170165374A1 (en) 2015-11-18 2017-06-15 Insmed, Inc. Compositions and methods for treating bacterial infections
MX2021011876A (es) 2019-03-29 2022-01-04 Glycomine Inc Formulaciones liposomicas y metodos de uso y preparacion de las mismas.

Also Published As

Publication number Publication date
TWI906214B (zh) 2025-12-01
EA202192663A1 (ru) 2022-03-01
KR20210143906A (ko) 2021-11-29
JP2022527638A (ja) 2022-06-02
IL286713B2 (en) 2025-07-01
SG11202110623PA (en) 2021-10-28
AU2020252005B2 (en) 2025-11-27
US12691131B2 (en) 2026-07-28
CN113873998A (zh) 2021-12-31
PH12021552428A1 (en) 2022-07-11
EP3946365A4 (en) 2023-04-19
AR119705A1 (es) 2022-01-05
CL2021002512A1 (es) 2023-01-06
IL286713A (en) 2021-10-31
IL286713B1 (en) 2025-03-01
PE20212366A1 (es) 2021-12-21
TW202102231A (zh) 2021-01-16
JP7583741B2 (ja) 2024-11-14
EP3946365A1 (en) 2022-02-09
BR112021019593A2 (pt) 2021-12-14
US20220184107A1 (en) 2022-06-16
AU2020252005A1 (en) 2021-11-04
WO2020205530A1 (en) 2020-10-08
CA3134828A1 (en) 2020-10-08
MX2021011876A (es) 2022-01-04

Similar Documents

Publication Publication Date Title
MX2026002469A (es) Nuevas moleculas de acido nucleico artificiales
MX2022003402A (es) Grupos principales de compuestos lipídicos y composiciones para la administración intracelular de agentes terapéuticos.
CO2019008684A2 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas para el tratamiento del cancer
BR112020026125A8 (pt) Compostos oligonucleotídeos superiores ou 5'-cap- trinucleotídeo e seus usos na estabilização de rna, expressão de proteínas e em terapia
EP4606890A3 (en) Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
BR112019000528A2 (pt) distribuição mediada por ve de conjugados de proteína de ligação-molécula pequena
AR110419A1 (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
MX2017005106A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
MX2018013995A (es) Células troncales mesenquimales y uso de las mismas para el tratamiento de lesiones musculares y enfermedades asociadas al músculo.
MX2016010519A (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
WO2015149944A3 (en) Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
MX2023011104A (es) Composiciones de polinucleotidos, formulaciones relacionadas y metodos de uso de las mismas.
BR112017016487A2 (pt) 7-benzil-4- (2-metilbenzil) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirrido [3,4-e] pirimidin-5 (1h) -ona, análogos desta, e sais do mesmo e métodos para sua utilização na terapia
NI201200172A (es) Activadores de guanilato ciclasa soluble
MX2021011876A (es) Formulaciones liposomicas y metodos de uso y preparacion de las mismas.
MX2022003039A (es) Metodo de seleccion de donantes universales para identificar donantes de celulas nk.
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
UY39969A (es) Ciertas octahidrofuro[3,4-b]pirazinas como moduladores del receptor de glp-1
MY206306A (en) Stable semaglutide compositions and uses thereof
BR112021020011A2 (pt) Preparação e armazenamento de formulações de rna lipossômico adequadas para terapia
MX2021005839A (es) Antagonistas del receptor de adenosina aminotriazolopirimidina y aminotriazolopirazina sustituidos, composiciones farmaceuticas y su uso.
BR112018067946A8 (pt) Formulações tópicas contendo ciclosporina e usos das mesmas
HK1252778A1 (zh) 细胞扩增方法和治疗组合物
AR039317A1 (es) Proceso para la preparacion de una suspension esteril de particulas de dipropionato de beclometasona para administracion por inhalacion